Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study
Choudhary P, Kolassa R, Keuthage W, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00212-1.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Risk of adverse events with liraglutide in HFrEF: a post‐hoc analysis of the FIGHT trial
Neves JS, Vasques-Nóvoa F, Borges-Canha M, et al.
Diabetes Obes Metab. Pub. online 9 Sep 2022.
Leggi
Benefit of dapagliflozin when used with cardiovascular medications in patients with type 2 diabetes
Slomski A
JAMA. 2022;328(9):817.
Leggi
Mean HbA1c and HbA1c variability are associated with differing diabetes-related complications in patients with type 2 diabetes mellitus
Wu TE, Su YW, Chen HS
Diabetes Res Clin Pract. 2022;110069.
Leggi
Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre® system initiation in people with type 2 diabetes on basal insulin therapy in France
Guerci B, Roussel R, Levrat-Guillen F, et al.
Diabetes Technol Ther. Pub. online 12 Sep 2022.
Leggi
Large effect size in composite kidney outcomes than in majors cardiovascular events of SGLT2 inhibitors compared with GLP-1 RAs: a pooled analysis of type 2 diabetes trials
Diallo A, Carlos-Bolumbu M, Renard E, Galtier F
Diabetes Obes Metab. Pub. online 3 Sep 2022.
Leggi
Effect of a comprehensive telehealth intervention vs telemonitoring and care coordination in patients with persistently poor type 2 diabetes control: a randomized clinical trial
Crowley MJ, Tarkington PE, Bosworth HB, et al.
JAMA Intern Med. 2022;182(9):943-952.
Leggi
Closed-loop therapy and preservation of c-peptide secretion in type 1 diabetes
Boughton CK, Allen JM, Ware J, et al.
N Engl J Med. 2022;387:882-893.
Leggi
Empagliflozin in acute myocardial infarction: the EMMY trial
von Lewinski D, Kolesnik E, Tripolt NJ, et al.
European Heart Journal. 2022;ehac494.
Leggi
Estimated event-free survival benefits with dapagliflozin in hf with mildly reduced or preserved ejection fraction
Vaduganathan M, Claggett BL, Jhund P et, al.
J Am Coll Cardiol. 2022;S0735-1097(22)06611-6
Leggi